Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.